Treatment of hepatitis C virus infection and associated glomerular disease

Abstract

Hepatitis C virus infection is a systemic disorder and can have various extrahepatic manifestations like hepatitis virus C associated glomerulonephritis. KDIGO recommends that all patients with hepatitis C virus infection be tested at least annually for proteinuria, hematuria and eGFR in order to detect a possible HCV-associated kidney disease. Immunossupressive therapy must be initiated in patients who have severe complications due to hepatitis virus C infection, but the clinicians must consider two aspects: hepatotoxicity and viral reactivation due to immunosuppression. As for antivirals, DAAs are now first-line treatment for management of HCV infection, even in CKD patients with advanced renal disease. In this review, we aimed to take a look on possible therapies for HCV-induced glomerulonephritis, the interactions beteween them and the impact of different therapies on renal and hepatic diseases.

Keywords

• hepatitis c virus
• immunosuppression
• daas
• ckd
• glomerulonephritis